Expression of neuroendocrine factor VGF in lung cancer cells confers resistance to EGFR kinase inhibitors and triggers epithelial-to-mesenchymal transition

Wen Hwang, Yu Fan Chiu, Ming Han Kuo, Kuan Lin Lee, An Chun Lee, Chia Cherng Yu, Junn Liang Chang, Wen Chien Huang, Shih Hsin Hsiao, Sey En Lin, Yu Ting Chou

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Mutations in EGFR drive tumor growth but render tumor cells sensitive to treatment with EGFR tyrosine kinase inhibitors (TKI). Phenotypic alteration in epithelial-to-mesenchymal transition (EMT) has been linked to the TKI resistance in lung adenocarcinoma. However, the mechanism underlying this resistance remains unclear. Here we report that high expression of a neuroendocrine factor termed VGF induces the transcription factor TWIST1 to facilitate TKI resistance, EMT, and cancer dissemination in a subset of lung adenocarcinoma cells. VGF silencing resensitized EGFR-mutated lung adenocarcinoma cells to TKI. Conversely, overexpression of VGF in sensitive cells conferred resistance to TKIs and induced EMT, increasing migratory and invasive behaviors. Correlation analysis revealed a significant association of VGF expression with advanced tumor grade and poor survival in patients with lung adenocarcinoma. In a mouse xenograft model of lung adenocarcinoma, suppressing VGF expression was sufficient to attenuate tumor growth. Overall, our findings show how VGF can confer TKI resistance and trigger EMT, suggesting its potential utility as a biomarker and therapeutic target in lung adenocarcinoma.

Original languageEnglish
Pages (from-to)3013-3026
Number of pages14
JournalCancer Research
Volume77
Issue number11
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Epithelial-Mesenchymal Transition
Lung Neoplasms
Phosphotransferases
Protein-Tyrosine Kinases
Neoplasms
Growth
Heterografts
Adenocarcinoma of lung
Transcription Factors
Biomarkers
Mutation
Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Expression of neuroendocrine factor VGF in lung cancer cells confers resistance to EGFR kinase inhibitors and triggers epithelial-to-mesenchymal transition. / Hwang, Wen; Chiu, Yu Fan; Kuo, Ming Han; Lee, Kuan Lin; Lee, An Chun; Yu, Chia Cherng; Chang, Junn Liang; Huang, Wen Chien; Hsiao, Shih Hsin; Lin, Sey En; Chou, Yu Ting.

In: Cancer Research, Vol. 77, No. 11, 01.06.2017, p. 3013-3026.

Research output: Contribution to journalArticle

Hwang, Wen ; Chiu, Yu Fan ; Kuo, Ming Han ; Lee, Kuan Lin ; Lee, An Chun ; Yu, Chia Cherng ; Chang, Junn Liang ; Huang, Wen Chien ; Hsiao, Shih Hsin ; Lin, Sey En ; Chou, Yu Ting. / Expression of neuroendocrine factor VGF in lung cancer cells confers resistance to EGFR kinase inhibitors and triggers epithelial-to-mesenchymal transition. In: Cancer Research. 2017 ; Vol. 77, No. 11. pp. 3013-3026.
@article{46aa82d8c5e14ec495b380f72a559247,
title = "Expression of neuroendocrine factor VGF in lung cancer cells confers resistance to EGFR kinase inhibitors and triggers epithelial-to-mesenchymal transition",
abstract = "Mutations in EGFR drive tumor growth but render tumor cells sensitive to treatment with EGFR tyrosine kinase inhibitors (TKI). Phenotypic alteration in epithelial-to-mesenchymal transition (EMT) has been linked to the TKI resistance in lung adenocarcinoma. However, the mechanism underlying this resistance remains unclear. Here we report that high expression of a neuroendocrine factor termed VGF induces the transcription factor TWIST1 to facilitate TKI resistance, EMT, and cancer dissemination in a subset of lung adenocarcinoma cells. VGF silencing resensitized EGFR-mutated lung adenocarcinoma cells to TKI. Conversely, overexpression of VGF in sensitive cells conferred resistance to TKIs and induced EMT, increasing migratory and invasive behaviors. Correlation analysis revealed a significant association of VGF expression with advanced tumor grade and poor survival in patients with lung adenocarcinoma. In a mouse xenograft model of lung adenocarcinoma, suppressing VGF expression was sufficient to attenuate tumor growth. Overall, our findings show how VGF can confer TKI resistance and trigger EMT, suggesting its potential utility as a biomarker and therapeutic target in lung adenocarcinoma.",
author = "Wen Hwang and Chiu, {Yu Fan} and Kuo, {Ming Han} and Lee, {Kuan Lin} and Lee, {An Chun} and Yu, {Chia Cherng} and Chang, {Junn Liang} and Huang, {Wen Chien} and Hsiao, {Shih Hsin} and Lin, {Sey En} and Chou, {Yu Ting}",
year = "2017",
month = "6",
day = "1",
doi = "10.1158/0008-5472.CAN-16-3168",
language = "English",
volume = "77",
pages = "3013--3026",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Expression of neuroendocrine factor VGF in lung cancer cells confers resistance to EGFR kinase inhibitors and triggers epithelial-to-mesenchymal transition

AU - Hwang, Wen

AU - Chiu, Yu Fan

AU - Kuo, Ming Han

AU - Lee, Kuan Lin

AU - Lee, An Chun

AU - Yu, Chia Cherng

AU - Chang, Junn Liang

AU - Huang, Wen Chien

AU - Hsiao, Shih Hsin

AU - Lin, Sey En

AU - Chou, Yu Ting

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Mutations in EGFR drive tumor growth but render tumor cells sensitive to treatment with EGFR tyrosine kinase inhibitors (TKI). Phenotypic alteration in epithelial-to-mesenchymal transition (EMT) has been linked to the TKI resistance in lung adenocarcinoma. However, the mechanism underlying this resistance remains unclear. Here we report that high expression of a neuroendocrine factor termed VGF induces the transcription factor TWIST1 to facilitate TKI resistance, EMT, and cancer dissemination in a subset of lung adenocarcinoma cells. VGF silencing resensitized EGFR-mutated lung adenocarcinoma cells to TKI. Conversely, overexpression of VGF in sensitive cells conferred resistance to TKIs and induced EMT, increasing migratory and invasive behaviors. Correlation analysis revealed a significant association of VGF expression with advanced tumor grade and poor survival in patients with lung adenocarcinoma. In a mouse xenograft model of lung adenocarcinoma, suppressing VGF expression was sufficient to attenuate tumor growth. Overall, our findings show how VGF can confer TKI resistance and trigger EMT, suggesting its potential utility as a biomarker and therapeutic target in lung adenocarcinoma.

AB - Mutations in EGFR drive tumor growth but render tumor cells sensitive to treatment with EGFR tyrosine kinase inhibitors (TKI). Phenotypic alteration in epithelial-to-mesenchymal transition (EMT) has been linked to the TKI resistance in lung adenocarcinoma. However, the mechanism underlying this resistance remains unclear. Here we report that high expression of a neuroendocrine factor termed VGF induces the transcription factor TWIST1 to facilitate TKI resistance, EMT, and cancer dissemination in a subset of lung adenocarcinoma cells. VGF silencing resensitized EGFR-mutated lung adenocarcinoma cells to TKI. Conversely, overexpression of VGF in sensitive cells conferred resistance to TKIs and induced EMT, increasing migratory and invasive behaviors. Correlation analysis revealed a significant association of VGF expression with advanced tumor grade and poor survival in patients with lung adenocarcinoma. In a mouse xenograft model of lung adenocarcinoma, suppressing VGF expression was sufficient to attenuate tumor growth. Overall, our findings show how VGF can confer TKI resistance and trigger EMT, suggesting its potential utility as a biomarker and therapeutic target in lung adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85020838533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020838533&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-16-3168

DO - 10.1158/0008-5472.CAN-16-3168

M3 - Article

C2 - 28381546

AN - SCOPUS:85020838533

VL - 77

SP - 3013

EP - 3026

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 11

ER -